| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | AVTX-009 (humanized monoclonal antibody) hidradenitis suppurativa | Phase 2 | — | Biologics | Dermatologic System | ||
phase 2 data readout example | AVTX-009 (humanized monoclonal antibody) hidradenitis suppurativa | Phase 2 | — | Biologics | Dermatologic System | ||
phase 2 data readout example | AVTX-009 (humanized monoclonal antibody) hidradenitis suppurativa | Phase 2 | — | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Avalo Therapeutics, Inc.$17.83
+0.75 (+4.39%)
C 51Pipeline Score Fair Value Pharma · Commercial
Market Cap
733.82 M
EPS
-5.82
P/E Ratio
-2.4 $
Value Trade
34.98 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
14.05 M
Operating CF
-17.69 M
Total Assets
99.89 M
Total Liabilities
31.57 M
Equity
68.32 M
D/E Ratio
12,345
-12.85 %
Week
12.84 %
1 Month
4.54 %
3 Month
-9.12 %
6 Month
-99.79 %
5 Year
-99.89 %
All Time
Cash Data
Cash Position
81.99 M
Monthly Burn
5.90 M
Runway
12.7 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
1.97 M
52 Week Range
4.06 - 24.27
% held by Insiders
8.98 %
% held by Institutions
76.36 %
Enterprise Value
654.00 M
Total Shares
24.51 M
Short %
30.07 %
Float Shares
21.22 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C51
Pipeline Score $806M
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored1.1x
rNPV / MCap Top 80%
Micro Cap (rank 182 of 905)
Percentile RankAvalo Therapeutics, Inc. carries a moderate pipeline score (51/100), with $6.1B risk-adjusted pipeline value, led by MDGN201 TARGTEPO in Chronic Kidney Disease (Phase 1), across $179B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDGN201 TARGTEPO Monoclonal antibody | Chronic Kidney Disease | Phase 1 | NCT02117427 | 27% | $3.9B | COMPLETED | 11 | - | - | Mar 20, 2017 | - | Oct 30, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AVTX-009 | hidradenitis suppurativa | Phase 2 | 2025-08-07 | |||
AVTX-009 | hidradenitis suppurativa | Phase 2 | 2025-08-07 | |||
AVTX-009 | hidradenitis suppurativa | Phase 2 | 2025-08-07 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
AVTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AVTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AVTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
AVTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
AVTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVTXAvalo Therapeutics Appoints Ron Philip to Board of Directors
Avalo Therapeutics has appointed Ron Philip to its Board of Directors, bringing over 30 years of biopharmaceutical experience. His expertise is expected to aid in advancing abdakibart, which recently showed positive Phase 2 results for hidradenitis suppurativa. The company is optimistic about the drug's potential as a best-in-disease treatment.
Read more →AVTXAvalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody aimed at treating hidradenitis suppurativa and other inflammatory disorders. The company plans to submit an IND application for AVTX-010 in the first half of 2027. This development follows positive topline data from their Phase 2 trial of abdakibart, further strengthening their pipeline.
Read more →AVTXAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - May 22, 2026
Avalo Therapeutics announced the grant of an inducement award of 34,000 stock options to a new employee, approved by the Compensation Committee. The award, compliant with Nasdaq Listing Rule 5635(c)(4), has an exercise price of $16.60 per share and will vest over four years. This move is part of Avalo's ongoing commitment to developing IL-1β-based treatments for immune-mediated inflammatory diseases.
Read more →AVTXAvalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics has granted an inducement award of stock options to a new employee, totaling 34,000 shares. This grant, approved under Nasdaq Listing Rule 5635(c)(4), is part of Avalo's strategy to incentivize talent. The options will vest over four years, beginning after one year of employment. Avalo is focused on developing IL-1β-based treatments for inflammatory diseases.
Read more →AVTXAvalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics reported positive topline results from its Phase 2 LOTUS trial for abdakibart in treating moderate to severe hidradenitis suppurativa. The trial met its primary endpoint, showing significant clinical improvement. The company also completed a public offering, raising $431.3 million to support its advancement into a Phase 3 program. Despite these successes, Avalo reported an increased net loss for the quarter.
Read more →AVTXAvalo Therapeutics Announces Pricing of $375 Million Public Offering
Avalo Therapeutics has announced the pricing of a public offering totaling $375 million, involving 19,730,000 shares of common stock and 1,400,000 pre-funded warrants. The offering is expected to close on May 7, 2026, pending customary conditions. Proceeds will be used to advance the clinical development of abdakibart and for general corporate purposes.
Read more →AVTXAvalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Avalo Therapeutics has initiated a public offering of common stock and pre-funded warrants. The proceeds will support the clinical development of abdakibart, particularly its Phase 3 topline data release. The offering is subject to market conditions, and the company has granted underwriters a 30-day option for additional shares. Recent positive data from a Phase 2 trial adds to the company's prospects.
Read more →AVTXAvalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics announced positive topline results from its Phase 2 LOTUS trial for abdakibart in treating moderate to severe hidradenitis suppurativa. The trial met its primary endpoint with significant response rates at both tested doses. Abdakibart was well tolerated, and the company plans to move forward with a phase 3 program based on these results.
Read more →AVTXAvalo Therapeutics Purchases Optional Milestone Buyout
Avalo Therapeutics has announced a Milestone Buyout Option Agreement related to its acquisition of AlmataBio. The agreement allows Avalo to pay $2.25 million for an option to pay an additional $5.125 million instead of a previously disclosed $15 million milestone payment. This move is part of Avalo's strategy to develop IL-1β-based treatments for immune-mediated inflammatory diseases.
Read more →AVTXAvalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Avalo Therapeutics reported its 2025 financial results, highlighting a significant cash reserve of approximately $98 million, which is expected to sustain operations until 2028. The company anticipates topline data from its Phase 2 LOTUS trial for abdakibart (AVTX-009) in treating hidradenitis suppurativa in the second quarter of 2026. However, the company also faced a notable increase in net loss and research expenses compared to the previous year.
Read more →AVTXAvalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics will participate in two upcoming investor conferences, including the TD Cowen Annual Healthcare Conference and the Leerink Partners Global Healthcare Conference. The company's lead asset, AVTX-009, is currently in a Phase 2 trial for hidradenitis suppurativa. This participation highlights Avalo's commitment to engaging with investors and promoting its innovative IL-1β-based treatments.
Read more →AVTXAvalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics has announced the grant of inducement equity awards amounting to 82,000 shares to two new employees as part of its compliance with Nasdaq Listing Rule 5635(c)(4). The stock options were issued at an exercise price reflecting the current market value and will vest over a four-year period. This move indicates a commitment to attracting new talent while the company continues to develop its IL-1β-based treatments for immune-mediated inflammatory diseases, particularly the ongoing Phase 2 trial for AVTX-009 aimed at hidradenitis suppurativa.
Read more →AVTXForward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical
Avalo Therapeutics is advancing its IL-1-targeting compound, AVTX-009, aimed at addressing unmet medical needs in hidradenitis suppurativa (HS). The company has completed enrollment for its Phase 2 LOTUS trial, with topline results expected by Q2 2026. Despite the optimistic prospects for the drug, the future remains uncertain due to various risks outlined in Avalo's forward-looking statements. The HS market shows potential for substantial growth, suggesting a favorable environment for AVTX-009's future development.
Read more →AVTXAvalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics reported its third quarter 2025 financial results, highlighting the completion of enrollment for the LOTUS trial. The company is now focused on finalizing the trial and preparing for data readout in mid-2026. CEO Dr. Garry Neil expressed confidence in AVTX-009's potential benefits for patients with hidradenitis suppurativa.
Read more →AVTXAvalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Avalo Therapeutics has completed enrollment in its Phase 2 LOTUS trial for AVTX-009, targeting hidradenitis suppurativa. The trial exceeded its enrollment goal with approximately 250 patients participating. Topline data is anticipated in mid-2026, and the trial aims to evaluate the efficacy and safety of AVTX-009 in treating this chronic condition.
Read more →AVTXAvalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Avalo Therapeutics has announced key appointments in its leadership team, naming Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President of Human Resources. These appointments come as the company prepares for a pivotal phase in its development of AVTX-009, currently in a Phase 2 trial for hidradenitis suppurativa. The new leaders bring extensive experience in business development and HR, aiming to enhance Avalo's organizational growth and strategic direction.
Read more →AVTXAvalo Therapeutics Appoints Kevin R. Lind to Board of Directors
Avalo Therapeutics has appointed Kevin R. Lind to its Board of Directors. Lind, who has over 20 years of experience in biotechnology and capital markets, is expected to contribute significantly to Avalo's mission, especially as the company advances its Phase 2 trial of AVTX-009 for hidradenitis suppurativa. His past success in leading Longboard Pharmaceuticals adds to his credibility.
Read more →AVTXAvalo Therapeutics Appoints Kevin R. Lind to the Board of Directors WAYNE, PA.
Avalo Therapeutics has appointed Kevin R. Lind to its Board of Directors, bringing over 20 years of experience in the biotechnology sector. Lind's leadership is anticipated to enhance Avalo's strategic direction, particularly as the company advances its Phase 2 clinical trial for AVTX-009 targeting hidradenitis suppurativa. Highlighting the potential of this treatment, the company aims to address significant unmet needs in immune-mediated inflammatory diseases. Lind's previous achievements include successful exits and capital raises in the biotech industry, which are expected to benefit Avalo in its mission for transformative therapies.
Read more →AVTXAvalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Avalo Therapeutics announced its second quarter 2025 financial results and business updates, highlighting significant progress in the Phase 2 LOTUS trial for hidradenitis suppurativa. The company has enrolled over 75% of the planned patients and anticipates completing enrollment by the end of 2025, with top-line results expected in mid-2026. Avalo remains dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases.
Read more →AVTXAvalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Avalo Therapeutics has appointed Dr. Rita Jain to its Board of Directors. Dr. Jain brings over two decades of experience in biopharmaceutical development and will support the advancement of AVTX-009, a monoclonal antibody in Phase 2 trials for hidradenitis suppurativa. Her expertise is expected to enhance Avalo's strategic growth in immunology and inflammation.
Read more →AVTXAvalo Reports First Quarter 2025 Financial Results and Recent Business Updates Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppura
Avalo Therapeutics reported its financial results for the first quarter of 2025, highlighting significant progress in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa. The company has appointed Mike Heffernan as Chairman of the Board and indicated that it has enough cash to sustain operations until at least 2027. However, they are also assessing the impact of market conditions on future development activities and second indication exploration. The net loss showed considerable reduction from the prior year, reflecting improved financial management amidst increased R&D costs.
Read more →AVTXForward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward- looking statements are statements that are not historica
Avalo Therapeutics, Inc. (AVTX) presents forward-looking statements regarding its lead compound AVTX-009, aimed at treating hidradenitis suppurativa (HS). The drug shows a high potential for efficacy and is positioned as a strong competitor in the market. Additionally, the company's financial outlook indicates sufficient funding to support operations through at least 2027. However, the success of these projections is contingent upon various external factors, including regulatory hurdles and clinical trial enrollment challenges.
Read more →AVTXAvalo Therapeutics to Participate in The Citizens Life Sciences Conference
Avalo Therapeutics, a clinical stage biotechnology company, will have its CEO, Dr. Garry Neil, present at the Citizens Life Sciences Conference in New York on May 8, 2025. The participation signifies the company's engagement with the market and its ongoing efforts in the treatment of immune dysregulation. Avalo's lead asset, AVTX-009, targets interleukin-1β, which plays a critical role in several inflammatory diseases. The archived webcast of the presentation will be accessible for viewers after the event.
Read more →AVTXAvalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE
Avalo Therapeutics has appointed Michael Heffernan as the new Chairman of the Board, succeeding Dr. Garry Neil who remains CEO. Heffernan's extensive biopharmaceutical experience is expected to drive the company's growth and advance its pipeline, particularly the Phase 2 LOTUS trial for AVTX-009, a treatment for hidradenitis suppurativa. The separation of the Chairman and CEO roles is viewed positively as Avalo prepares for potential expansion and data readouts in the coming year.
Read more →AVTXAvalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy
Avalo Therapeutics, Inc. has reported its financial results for the year 2024, showcasing a net loss of $35.1 million, an increase from the previous year. The company highlighted its cash reserves of approximately $135 million, which are expected to fund operations through 2027. Significant developments include the initiation of the Phase 2 LOTUS trial for its drug AVTX-009, targeting hidradenitis suppurativa, with topline results projected for 2026. Jennifer Riley has been appointed as the Chief Strategy Officer to lead strategic initiatives and pipeline planning.
Read more →AVTXAvalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Avalo Therapeutics, a clinical-stage biotechnology firm focused on immune dysregulation, announced that CEO Garry A. Neil will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The event will be available via live webcast and archived for 30 days. Avalo’s lead candidate, AVTX-009, targets IL-1β and aims to provide therapeutic options for various inflammatory conditions. The company has additional candidates in its pipeline, emphasizing its dedication to developing treatments in this area.
Read more →AVTXAvalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer WAYNE
Avalo Therapeutics has appointed Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In her new role, Ms. Riley will oversee corporate strategy, focusing on growth and the product pipeline, which includes the lead asset AVTX-009 in a Phase 2 trial for hidradenitis suppurativa. Her extensive background in biotechnology and pharmaceutical industries positions her well to advance Avalo’s mission and explore new treatment opportunities. The appointment is expected to strengthen Avalo's strategic focus and commercialization strategies.
Read more →AVTXAvalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total
Avalo Therapeutics has successfully completed the full exercise of its private placement warrants, generating gross proceeds of $69.4 million from investors. This brings the total gross proceeds from the March 2024 private placement to $185 million, significantly enhancing the company's cash runway into at least 2027. With this funding, Avalo intends to focus on executing its Phase 2 LOTUS trial for its lead asset AVTX-009, as well as exploring additional indications for this drug targeting immune dysregulation. The company expressed gratitude for the support of its investors in this financing move.
Read more →AVTXAvalo Therapeutics to Present at Upcoming Investor Conferences
Avalo Therapeutics, a clinical stage biotechnology company, has announced that its CEO, Dr. Garry A. Neil, will present at two upcoming investor conferences in New York. The presentations are scheduled for November 18 and December 5, 2024, at the Stifel and Piper Sandler Healthcare Conferences, respectively. The company focuses on treatments for immune dysregulation, highlighted by its lead asset AVTX-009, an anti-IL-1β monoclonal antibody. The drug targets inflammatory diseases, showing potential in various therapeutic areas.
Read more →AVTXAvalo Reports Third Quarter 2024 Financial Results and Recent Business Updates Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026
Avalo Therapeutics reported its financial results for Q3 2024, noting significant progress in its clinical programs, particularly the dosing of the first patient in the Phase 2 LOTUS trial for AVTX-009, targeting hidradenitis suppurativa. The company's cash position is robust, with $82 million available to support operations through at least 2027. However, the topline data for the LOTUS trial is not expected until 2026, leaving uncertain timelines for potential treatment outcomes. Avalo also highlighted an increase in operating expenses associated with the trial's initiation and related activities.
Read more →AVTXAvalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safet
Avalo Therapeutics has announced that the first patient has been dosed in its Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa. This trial aims to evaluate the efficacy and safety of AVTX-009, a humanized monoclonal antibody targeting interleukin-1, compared to a placebo in approximately 180 adults. Topline data from the trial is anticipated to be released in 2026, addressing a significant need for improved treatments in this chronic inflammatory skin condition.
Read more →AVTXAvalo Announces Participation in September Investor Conferences
Avalo Therapeutics, Inc. announced that its CEO, Garry A. Neil, will present at two investor conferences in September 2024. The presentations include a pre-recorded session at the H.C. Wainwright Annual Global Investment Conference and a fireside chat at the Stifel Virtual Immunology and Inflammation Summit. Both events aim to enhance investor engagement and showcase Avalo’s developments in treating immune dysregulation, particularly involving their lead asset, AVTX-009.
Read more →AVTXAvalo Reports Second Quarter 2024 Financial Results and Provides Business Updates Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024 Appointed Dr. Mi
Avalo Therapeutics has announced its financial results for Q2 2024 and shared updates on its clinical progress. It plans to initiate the Phase 2 LOTUS Trial for its AVTX-009 treatment targeting hidradenitis suppurativa, aiming to enroll the first patient by the end of 2024. The company has appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal Officer, strengthening its leadership team. Despite a reported net loss of $22.8 million, Avalo maintains a strong cash position with approximately $93.4 million available, projected to sustain operations until 2027.
Read more →AVTXAvalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer WAYNE, PA and ROCKVILLE, MD
Avalo Therapeutics has appointed Dr. Mittie Doyle as its new Chief Medical Officer, bringing over 20 years of experience in the pharmaceutical biotech sector. Dr. Doyle will lead the company as it prepares to initiate the Phase 2 LOTUS Trial for AVTX-009, targeting hidradenitis suppurativa. Her leadership is expected to be vital in guiding the drug's development in inflammatory conditions. Dr. Doyle expresses optimism about AVTX-009's potential to significantly improve patient quality of life.
Read more →AVTXAvalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1 mAb, to Treat Hidradenitis Suppurativa Following FDA review, Avalo's IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 tr
Avalo Therapeutics has announced that its Investigational New Drug application for AVTX-009, an anti-IL-1 monoclonal antibody, has been approved by the FDA, allowing the company to initiate its Phase 2 LOTUS clinical trial for the treatment of hidradenitis suppurativa. The trial is set to evaluate the efficacy and safety of AVTX-009 in about 180 adults suffering from moderate to severe hidradenitis suppurativa. The company anticipates enrolling the first patient in the trial later this year, marking a significant step in the development of this treatment for a condition with limited therapeutic options.
Read more →AVTXAvalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer WAYNE, PA and ROCKVILLE, MD
Avalo Therapeutics has appointed Paul Varki as its Chief Legal Officer. Varki, who has more than 20 years of industry experience, is expected to strengthen Avalo's strategic and legal competencies, especially as the company advances its lead asset, AVTX-009, in hidradenitis suppurativa and other autoimmune indications. The appointment follows Avalo's recent acquisition and private placement, signaling an exciting growth phase for the company. As part of his compensation, Varki has been granted stock options to purchase 150,000 shares of Avalo stock, vesting over four years.
Read more →AVTXAvalo to Present at the Oppenheimer Novel Targets in Immunology Summit
Avalo Therapeutics, Inc. announced that its CEO Garry A. Neil will present at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024. Neil will speak on the panel addressing novel immunological mechanisms related to dermatological disorders. Avalo focuses on treating immune dysregulation, with its lead asset being AVTX-009, an anti-IL-1β monoclonal antibody aimed at inflammatory diseases. The summit highlights Avalo's commitment to advancing research in this crucial area.
Read more →AVTXAvalo Reports First Quarter 2024 Financial Results and Provides Business Updates Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 Cash on hand of approximately $110 mill
Avalo Therapeutics announced its financial results for the first quarter of 2024, reporting a net loss of $121.3 million. The company possesses approximately $110 million in cash and has a planned cash runway extending into 2027. It is making progress toward the initiation of a Phase 2 trial for AVTX-009 in hidradenitis suppurativa, with topline results expected in 2026. The company is also conducting strategic reviews of its other programs and planning to develop AVTX-009 for additional indications.
Read more →AVTXAvalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Therapeutics has announced the appointment of new Independent Directors, including industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex. This move is part of Avalo's strategy to enhance its leadership as it focuses on the development of its monoclonal antibody AVTX-009, aimed at treating autoimmune diseases. The company has also secured up to $185 million in private placement financing to support its initiatives. The newly appointed directors bring extensive experience from various sectors in biotech and life sciences.
Read more →AVTXAvalo Reports 2023 Financial Results and Provides Business Updates Acquired AVTX-009, Phase-2 ready anti-IL-1 mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185
Avalo Therapeutics reported its financial results for 2023, highlighting a successful acquisition of AVTX-009, an anti-IL-1 monoclonal antibody. The company secured up to $185 million in private placement financing, providing necessary resources for the drug's development. Topline data from the Phase 2 trial for AVTX-009 in hidradenitis suppurativa is anticipated in 2026. Despite the positive cash infusion, Avalo continues to deal with a significant accumulated deficit.
Read more →AVTXAvalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million Avalo acquires Phase 2-ready anti-IL-1 mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase
Avalo Therapeutics has announced the acquisition of Phase 2-ready anti-IL-1 monoclonal antibody AVTX-009 from AlmataBio, aiming to develop it for hidradenitis suppurativa. Concurrently, Avalo secured a private placement financing of up to $185 million to support this acquisition and fund operations through to the Phase 2 trial results expected in 2026. The investment will help Avalo target both hidradenitis suppurativa and potentially other chronic inflammatory indications. The company's leadership and strategic funding position it favorably for future developments in the treatment of autoimmune diseases.
Read more →AVTXAvalo Therapeutics Announces 1-for-240 Reverse Stock Split
Avalo Therapeutics has announced a 1-for-240 reverse stock split intended to raise the per share price of its common stock, facilitating compliance with Nasdaq Capital Market listing requirements. As of December 28, 2023, the stock will begin trading on a split-adjusted basis. The reverse stock split will reduce the number of outstanding shares but will not change stockholder ownership percentages overall. The company aims to address its stock performance challenges, which raise concerns about its financial stability and future capital needs.
Read more →AVTXAvalo Encourages Stockholders to Vote FOR the Reverse Stock Split Annual Meeting has been adjourned until
Avalo Therapeutics is urging its stockholders to vote in favor of a reverse stock split during the adjourned annual meeting scheduled for December 20, 2023. The initial meeting did not meet the necessary quorum for the proposal to pass. The company emphasizes that a successful vote is crucial for maintaining its Nasdaq listing and facilitating future fundraising efforts. Management warns that lack of approval could hinder strategic initiatives and negatively impact shareholders.
Read more →AVTXAvalo Reports Third Quarter 2023 Financial Results and Provides Business Updates Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone p
Avalo Therapeutics reported strong advancements in their third quarter 2023 results, notably paying off a $35 million debt, which improves their financial position. The company divested its AVTX-800 series for potential milestone payments of up to $45 million, allowing for a sharper focus on their immunology pipeline. Dr. Garry Neil expressed enthusiasm for progressing quisovalimab, an anti-LIGHT monoclonal antibody, towards potential trials in ulcerative colitis and other inflammatory diseases. However, the company reported a net loss and a decrease in interim revenues, indicating challenges despite their strategic progress.
Read more →AVTXAvalo Completes Divestiture of AVTX-800 Series WAYNE
Avalo Therapeutics, Inc. has finalized the sale of its AVTX-800 Series assets to AUG Therapeutics, receiving an upfront payment of $150,000 and potential milestone payments totaling $45 million. The divestiture allows Avalo to concentrate on its immunology assets, which they believe hold greater promise for shareholder value. AUG is tasked with advancing the treatment programs targeting congenital disorders of glycosylation. Management expressed optimism about the immediate positive effect on cash flow and the potential benefits this transition holds for patients.
Read more →AVTXAvalo Completes Divestiture of AVTX-800 Series
Avalo Therapeutics, Inc. has finalized the divestiture of its AVTX-800 series assets to AUG Therapeutics, LLC for $150,000, with potential milestone payments totaling up to $45 million. The CEO expressed optimism about the transaction, emphasizing that it allows the company to concentrate on its immunology portfolio, which is seen as more promising for addressing unmet medical needs. The company aims to enhance its cash flow and improve shareholder value through this strategic shift.
Read more →AVTXAvalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation WAYNE
Avalo Therapeutics has successfully paid off its $35 million debt to Horizon Technology Finance Corporation, representing a significant step towards financial stability. This milestone is expected to enable the company to pursue accelerated growth and advance its drug development programs, particularly for its candidates, quisovalimab and AVTX-008. CEO Dr. Garry Neil highlighted the achievement as a pivotal moment for Avalo, signaling readiness to explore new opportunities and enhance their pipeline. The accomplishment also reflects the company's operational excellence amidst a challenging biotechnology environment.
Read more →AVTXAvalo Enters into Agreement to Divest AVTX-800 Series WAYNE
Avalo Therapeutics has entered a purchase agreement with AUG Therapeutics to divest its AVTX-800 series, including compounds AVTX-801, AVTX-802, and AVTX-803. The deal involves an upfront payment of $150,000, with potential contingent milestone payments up to $45 million. This divestiture aligns with Avalo's strategic focus on immunology assets and is expected to improve cash flow while reducing resource usage for non-core activities. The transaction is anticipated to close in the fourth quarter of 2023, contingent upon customary closing conditions.
Read more →AVTXCopyright 2023. Avalo Therapeutics. All rights reserved. This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are stat
Avalo Therapeutics presented data from its PEAK trial regarding AVTX-002, highlighting its effectiveness in significantly reducing LIGHT levels and exhibiting a favorable safety profile. Preliminary analyses indicated promising outcomes for a subset of patients with elevated baseline LIGHT levels. The company is progressing with its portfolio, including future studies for potential biologics aimed at inflammatory diseases. The overall sentiment reflects optimism regarding the ongoing developments and the efficacy of AVTX-002.
Read more →AVTXAvalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Avalo Therapeutics, Inc. announced that its CEO, Dr. Garry A. Neil, will present at the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. The pre-recorded presentation will be available on September 11 at 7:00 AM ET and can be accessed via the company’s website. The announcement highlights Avalo's focus on developing therapies aimed at treating immune dysregulation through its exploration of the LIGHT-signaling network.
Read more →AVTXAvalo Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002
Avalo Therapeutics recently reported its financial results for Q2 2023, revealing that its lead candidate AVTX-002 did not meet the primary endpoint in the Phase 2 PEAK trial for non-eosinophilic asthma. Despite this setback, the trial indicated that AVTX-002 significantly reduces serum LIGHT levels, suggesting potential in other inflammatory conditions. The company is facing financial challenges, including a cash decrease and a forbearance agreement with lenders. Future development plans for AVTX-002 and other assets remain a focus for Avalo.
Read more →AVTXAvalo to Participate in SVB Securities Therapeutics Forum
Avalo Therapeutics, Inc. announced that CEO Garry A. Neil will participate in the SVB Securities Therapeutics Forum scheduled for July 11-12, 2023, in New York. The forum gives Avalo the chance to highlight its work in developing therapies for immune dysregulation, specifically targeting the LIGHT-signaling network. This event may provide valuable networking opportunities, as well as insights into potential strategic collaborations within the industry.
Read more →AVTXAvalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared
Avalo Therapeutics announced topline results from its Phase 2 PEAK trial evaluating AVTX-002 in patients with non-eosinophilic asthma. The trial did not meet its primary endpoint of reducing asthma-related events, though AVTX-002 showed a favorable safety profile and a significant reduction in serum LIGHT levels. Additionally, a positive trend was noted in patients with elevated baseline LIGHT levels, suggesting potential for future therapy. Further analyses are underway to clarify patient response and future directions in treatment.
Read more →AVTXAvalo to Present at the Jefferies Healthcare Conference
Avalo Therapeutics, Inc. announced that its CEO, Dr. Garry A. Neil, will deliver a presentation at the Jefferies Healthcare Conference on June 9, 2023. The event will take place at the Marriott Marquis in New York City, and a live webcast will be accessible via the company's website. Avalo is a clinical-stage biotechnology company concentrating on developing therapies for immune dysregulation, focusing on the LIGHT network's role in various inflammatory disorders.
Read more →AVTXAvalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
Avalo Therapeutics has announced the addition of Dr. Michael Croft and Dr. Jeff Edelson to its Scientific Advisory Board. This board, led by Dr. Carl Ware, is comprised of experts in immunology, particularly in the LIGHT-signaling network. The appointments are expected to bolster Avalo’s scientific strategy as the company approaches a key data readout for its Phase 2 PEAK trial of AVTX-002. Both new members bring extensive research experience and industry knowledge to aid in the development of therapies targeting immune dysregulation.
Read more →AVTXAvalo to Present at ATS 2023 Respiratory Innovation Summit
Avalo Therapeutics, Inc. announced that its CEO, Dr. Garry A. Neil, will present at the ATS 2023 Respiratory Innovation Summit on May 20, 2023. The presentation will focus on AVTX-002, Avalo's lead candidate for treating non-eosinophilic asthma. The Phase 2 PEAK Trial is currently assessing the safety and efficacy of AVTX-002 in patients with poorly controlled asthma. The trial results may contribute to Avalo's understanding of the drug's potential in managing asthma-related complications.
Read more →AVTXAvalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
Avalo Therapeutics, Inc. has announced that its CEO, Garry A. Neil, will present at the 2023 RBC Capital Markets Global Healthcare Conference on May 16, 2023. This presentation will focus on the company's efforts in developing therapies aimed at treating immune dysregulation through the LIGHT network. A live webcast of the event will be accessible on Avalo's website. The announcement highlights Avalo's commitment to addressing various immune-related disorders and marks an important engagement in the healthcare sector.
Read more →AVTXAvalo Reports First Quarter 2023 Financial Results and Provides Business Updates Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) Disclosed cash
Avalo Therapeutics reported its financial results for the first quarter of 2023, disclosing approximately $16.7 million in cash as of March 31. The company is on the verge of releasing topline data from its Phase 2 PEAK Trial for AVTX-002, targeted at non-eosinophilic asthma (NEA). Although expenses have decreased, Avalo posted a net loss of $9.95 million for the quarter, highlighting financial pressures despite some recent positive developments.
Read more →AVTXAvalo Reports 2022 Financial Results and Provides Business Updates Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) topline data expected in the second quarter of 2023 Disclosed
Avalo Therapeutics reported its financial results for 2022, showing a reduced net loss compared to the previous year, largely due to decreased operating expenses. The company completed enrollment in the Phase 2 PEAK Trial of AVTX-002 for non-eosinophilic asthma, with topline data expected in Q2 2023. Financially, Avalo improved its position through a recent public stock offering that raised $15 million, although cash reserves declined significantly from the previous year. The company continues to focus on its lead development asset AVTX-002 and has also identified a new candidate aimed at immune dysregulation disorders.
Read more →AVTXAvalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
Avalo Therapeutics, Inc. announced that its CEO, Garry A. Neil, will present virtually at the Oppenheimer's 33rd Annual Healthcare Conference on March 13, 2023. The conference presentation will focus on the company's efforts in developing therapies that target the LIGHT network for immune dysregulation treatment. Avalo emphasizes the potential impact of its research on autoimmune and inflammatory disorders. However, the company also faces several operational risks, including its financial position and regulatory challenges.
Read more →AVTXAvalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
Avalo Therapeutics, Inc. has announced the pricing of a public offering to raise $15 million by selling 3,770,000 shares of common stock and related warrants. The offering, priced at $3.98 per share and warrant, is expected to close on February 7, 2023, pending customary conditions. Proceeds from the offering will support Avalo's development of therapies targeting immune dysregulation. However, the company faces ongoing market uncertainties and potential future financing needs.
Read more →AVTXAvalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants WAYNE
Avalo Therapeutics, Inc. has announced a proposed public offering of its common stock and associated warrants, intending to raise capital for further development. The offering will be conducted under an existing shelf registration statement and managed by SVB Securities and RBC Capital Markets. However, the completion of this offering is contingent on market conditions, and the company's actual financial needs are still under evaluation. The final terms will be detailed in a forthcoming prospectus supplement.
Read more →AVTXAvalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma Topline data expected in the second quarter of 2023 WAYNE
Avalo Therapeutics has completed the targeted enrollment of 80 patients in the Phase 2 PEAK Trial for AVTX-002, aimed at treating Non-Eosinophilic Asthma (NEA). Additional patients currently in the run-in period will also be allowed to complete enrollment. The trial is designed to assess the safety and efficacy of AVTX-002 over a 12-week period, with topline data anticipated in the second quarter of 2023. This trial represents an important step in Avalo's efforts to explore treatment options for patients suffering from inflammatory diseases related to asthma.
Read more →AVTXAvalo Reports Third Quarter 2022 Financial Results and Provides Business Updates Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) Entered into agree
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA) Entered into agreement to sell future economic rights to previously out-lice
Read more →AVTXAvalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future payments for previously out-licensed assets including AVTX-007, AVTX-501, and AVTX-
Read more →AVTXAvalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
Strategy focused on LIGHT-signaling network targets WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced today that its human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein, AVTX-008, has now entered IND
Read more →AVTXAvalo to Present at the H.C. Wainwright Global Investment Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held Septemb
Read more →AVTXAvalo Therapeutics Announces Board Changes
WAYNE, Pa. and ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Mas
Read more →AVTXAvalo Therapeutics Announces Board Changes WAYNE
Avalo Therapeutics Announces Board Changes WAYNE, PA AND ROCKVILLE, MD, August 11, 2022 - Avalo Therapeutics, Inc. (Nasdaq AVTX) announced today that on August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital M
Read more →AVTXAvalo Reports Second Quarter 2022 Financial Results and Provides Business Updates Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront p
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates Transferred anti-IL 18 monoclonal antibody product (AVTX-007) to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in August Dosed first patient in the Phas
Read more →AVTXAvalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy an
Read more →AVTXAvalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments Apollo to lead conti
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments Apollo to lead continued clinical development of AVTX-007, currently in Phase
Read more →AVTXAvalo Therapeutics Announces One-for-Twelve Reverse Stock Split
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022. T
Read more →AVTXAvalo to Present at the 2022 Jefferies Healthcare Conference
WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 4:00 PM
Read more →AVTXAvalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non- Eosinophilic Asthma (NEA) Topline results expected 4Q2022 WAYNE, Pa.
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non- Eosinophilic Asthma (NEA) Topline results expected 4Q2022 WAYNE, Pa. AND ROCKVILLE, Md., May 18, 2022 - Avalo Therapeutics, Inc. (Nasdaq AVTX), announced that the fi
Read more →AVTXAvalo to Present at the H.C. Wainwright Global Life Sciences Conference
WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Life Sciences Conference being held May 23
Read more →AVTXAvalo Therapeutics First Quarter 2022 Financial Results and Business Updates Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte a
Avalo Therapeutics First Quarter 2022 Financial Results and Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion deficiency type II (LAD II) Executed workforce reduction to align w
Read more →AVTXavtxxirxdeckxfina 1 Copyright 2022. Avalo Therapeutics. All rights reserved. Avalo is a leading clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize
Abstract 725. 10. R rvig et al J Leukocyte Biol 94, 711-721 (2013). Treatment Approach4 Typical asthma symptoms; often more severe/resistant to treatment5 Associated with smoking, pollution, infections, obesity5 Sputum LIGHT levels negatively associated with lung function (FEV1 a
Read more →AVTXAvalo to Present at Oppenheimer's 32nd Annual Healthcare Conference
WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in i
Read more →AVTXAvalo Therapeutics Reports 2021 Financial Results and Provides Business Updates Dr. Garry Neil and Chris Sullivan promoted to Chief Executive Officer and Chief Financial Officer, respectively Announced plans to initiate
Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates Dr. Garry Neil and Chris Sullivan promoted to Chief Executive Officer and Chief Financial Officer, respectively Announced plans to initiate a Phase 2 randomized, double-blind, placebo-controlled tr
Read more →AVTXAvalo Therapeutics Announces Leadership Transition Promotes Dr. Garry Neil to Chief Executive Officer Promotes Chris Sullivan to Chief Financial Officer WAYNE
Avalo Therapeutics Announces Leadership Transition Promotes Dr. Garry Neil to Chief Executive Officer Promotes Chris Sullivan to Chief Financial Officer WAYNE, PA AND ROCKVILLE, MD, February 17, 2022 - Avalo Therapeutics, Inc. (Nasdaq AVTX), a leading clinical-stage precision
Read more →AVTXAvalo Therapeutics to Present at the 2022 BIO CEO and Investor Conference
WAYNE, Pa. and ROCKVILLE, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in im
Read more →AVTXAvalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
WAYNE, Pa. and ROCKVILLE, Md., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo” or the “Company”), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significan
Read more →AVTXAvalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event Immunology portfolio highlighted by success of a second p
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mec
Read more →AVTXAvalo Therapeutics to Host Virtual Investor Day on January 6, 2022
WAYNE, Pa. and ROCKVILLE, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in im
Read more →AVTXAvalo Appoints Two New Independent Directors to Its Board WAYNE
Avalo Appoints Two New Independent Directors to Its Board WAYNE, PA AND ROCKVILLE, MD, December 6, 2021 - Avalo Therapeutics, Inc. (Nasdaq AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients w
Read more →AVTXAvalo to Present at Two Upcoming Conferences
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in im
Read more →AVTXAvalo Reports Third Quarter 2021 Financial Results and Provides Business Updates Topline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021 Multiple data read
Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates Topline Phase 1b data for AVTX-002 in moderate to severe Crohn's disease patients expected in the fourth quarter of 2021 Multiple data readouts across programs anticipated within the next six month
Read more →AVTXAvalo to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
WAYNE, Pa. and ROCKVILLE, Md., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in im
Read more →AVTXAvalo to Present at the 2021 Cantor Virtual Global Healthcare Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in i
Read more →AVTXAvalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa
Read more →AVTXAvalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa
Read more →AVTXAvalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock WAYNE, Pa. and ROCKVILLE, Md.
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 - Avalo Therapeutics, Inc. ("Avalo" or the "Company") (Nasdaq AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commer
Read more →AVTXCopyright 2021. Avalo Therapeutics, Inc. All rights reserved. Innovation Driven by Compassion September 2021 2 Copyright 2021. Avalo Therapeutics, Inc. All rights reserved. This presentation may include forward - looking
Jeffrey Wilkins, MD | Chief Medical Officer Former VP, Worldwide Clinical Research, Inflammation/Oncology at Cephalon and SVP of Clinical Development with Ception Therapeutics Former VP of Discovery Medicine for GSK's Center of Excellence in External Drug Disc overy Proven Track
Read more →AVTXAvalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc. Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic dis
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc. Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseases Robust pipeline of six product candidates advancing
Read more →AVTXCerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates Announced positive results for low-dose cohort of CERC-002 (1.0 mg kg) in moderate-to-severe Crohn's disease patients who had previously
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates Announced positive results for low-dose cohort of CERC-002 (1.0 mg kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, includin
Read more →AVTXCerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients Positive results for low-dose cohort of CERC-002 (1.0 mg kg) in moderate to severe Crohn's disease patients
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients Positive results for low-dose cohort of CERC-002 (1.0 mg kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic t
Read more →AVTXRisks Related to our Financial Position Raising funds through lending arrangements may restrict our operations or produce other adverse results. Our current loan agreement (the "Loan Agreement") with Horizon Technology F
Risks Related to our Financial Position Raising funds through lending arrangements may restrict our operations or produce other adverse results. Our current loan agreement (the "Loan Agreement") with Horizon Technology Finance Corporation and Powerscourt Investments XXV, LP (co
Read more →AVTXCerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets Cerecor completes divestiture of non-core neurology pipeline assets as it increa
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare gene
Read more →AVTXCerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance An initial tranche of $20 million drawn at the loan closing Funds ongoing clinical development of key investigational product candi
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance An initial tranche of $20 million drawn at the loan closing Funds ongoing clinical development of key investigational product candidates Financing provides flexibility and extends runway t
Read more →AVTXCerecor Reports First Quarter 2021 Financial Results and Provides Business Updates Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19 AR
Read more →AVTXCerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002 Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indicatio
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002 Expanded agreement for exclusive, world-wide rights to develop, manufacture and commercialize CERC-002 for all indications including severe pediatric onset inflammatory bowel dise
Read more →AVTXCerecor Reports 2020 Financial Results and Provides Business Updates Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS Improv
Cerecor Reports 2020 Financial Results and Provides Business Updates Announced CERC-002 significantly reduced respiratory failure and mortality in Phase 2 clinical trial in patients hospitalized with COVID-19 ARDS Improved financial position with $18.9M of cash on hand as of De
Read more →AVTXCerecor Appoints Schond L. Greenway as Chief Financial Officer - Announces inducement grant under NASDAQ Listing Rule 5635(c)(4) ROCKVILLE, Md. and CHESTERBROOK, Pa.
Cerecor Appoints Schond L. Greenway as Chief Financial Officer - Announces inducement grant under NASDAQ Listing Rule 5635(c)(4) ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 -- Cerecor Inc. (NASDAQ CERC), a biopharmaceutical company focused on becoming a leader in the d
Read more →AVTXC erecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants ROCKVILLE, MD and CHESTERBROOK, PA
Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants ROCKVILLE, MD and CHESTERBROOK, PA, January 7, 2021 - Cerecor Inc. (Nasdaq CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments f
Read more →AVTXCerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoc
Cerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in
Read more →AVTXCerecor Reports Third Quarter 2020 Financial Results and Provides Business Update On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end Strengthened leadership team with the
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end Strengthened leadership team with the appointment of Gilla Kaplan, Ph.D., to the Board of Direc
Read more →AVTXCerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors ROCKVILLE, Md. and CHESTERBROOK, Pa.
Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 - Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan dise
Read more →AVTXCerecor Reports Second Quarter 2020 Financial Results and Business Update -Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient
Cerecor Reports Second Quarter 2020 Financial Results and Business Update -Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the preve
Read more →AVTXCerecor Inc. Announces Proposed Public Offering of Common Stock ROCKVILLE, MD
Cerecor Inc. Announces Proposed Public Offering of Common Stock ROCKVILLE, MD, June 8, 2020 - Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announce
Read more →AVTXCerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS Company to Initiate Multicenter, Placebo-controlled, Randomized Study in June Top-line Data Anticipated in Fourth Quarter 2020 Rockville, MD
Cerecor Announces FDA Clearance of IND for CERC-002 in COVID-19 Induced ARDS Company to Initiate Multicenter, Placebo-controlled, Randomized Study in June Top-line Data Anticipated in Fourth Quarter 2020 Rockville, MD - May 28, 2020 -- Cerecor Inc. (NASDAQ: CERC), a biopharmac
Read more →AVTXCerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study - Patients hospitalized with COVID-19 had significa
Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study - Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT -
Read more →AVTXCerecor Reports Q1 2020 Results and Update -Significantly Improved Cash Position and Balance Sheet -Closed Aevi Merger; Transformed into Orphan and Rare Disease Biotech ROCKVILLE, MD
Cerecor Reports Q1 2020 Results and Update -Significantly Improved Cash Position and Balance Sheet -Closed Aevi Merger; Transformed into Orphan and Rare Disease Biotech ROCKVILLE, MD - May 07, 2020 -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming
Read more →AVTXCerecor Announces Changes to Board of Directors -Appoints Sol J. Barer, Ph.D. as Chairman of the Board - Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board Rockville, MD
Cerecor Announces Changes to Board of Directors -Appoints Sol J. Barer, Ph.D. as Chairman of the Board - Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board Rockville, MD, April 24, 2020 - Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused o
Read more →AVTXCerecor Reports 2019 Results
Cerecor Reports 2019 Results -Company Transformed Into Orphan and Rare Disease Biotech -Clear Corporate Strategy with New Leadership -Significant Advancement in Pipeline and Regulatory Milestones Rockville, MD - March 11, 2020 -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutic
Read more →AVTXCerecor and Aevi Genomic Medicine Complete Merger -Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medi
Cerecor and Aevi Genomic Medicine Complete Merger -Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer Rockville, MD, February 3, 2020 - Cerecor Inc
Read more →AVTXUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial statements are based upon the historical consolidated statements of Cerecor Inc. ("Cerecor" or t
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial statements are based upon the historical consolidated statements of Cerecor Inc. ("Cerecor" or the "Company"), adjusted to give the effects directly attrib
Read more →AVTXCerecor to Acquire Aevi Genomic Medicine -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Ch
Cerecor to Acquire Aevi Genomic Medicine -Expands Clinical-stage Pipeline, Further Positioning Cerecor as a leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explore
Read more →AVTXCerecor Reports Third Quarter 2019 Results -Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 Million -First Patient Enrolled in Diabetic OH Trial with CERC-301 -Completed Phase 1 Healthy Volunteer Study with
Cerecor Reports Third Quarter 2019 Results -Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 Million -First Patient Enrolled in Diabetic OH Trial with CERC-301 -Completed Phase 1 Healthy Volunteer Study with CERC-802 -CERC-802 IND Accepted by FDA and Received Fas
Read more →AVTXCerecor Closes Deal to Sell Pediatric Portfolio Rockville, MD
Cerecor Closes Deal to Sell Pediatric Portfolio Rockville, MD - November 4, 2019 -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan diseases and neurology, announced today that it
Read more →AVTXCerecor To Sell Pediatric Portfolio to AYTU BioScience -Deal Valued in Excess of $32 Million -Eliminates Debt Associated with Avadel / Deerfield Agreement -Provides Non-Dilutive Cash Generation to Fund R&D -Extends Runwa
Cerecor To Sell Pediatric Portfolio to AYTU BioScience -Deal Valued in Excess of $32 Million -Eliminates Debt Associated with Avadel / Deerfield Agreement -Provides Non-Dilutive Cash Generation to Fund R&D -Extends Runway Towards NDA Submission of CERC-801 Rockville, MD - Oc
Read more →AVTXCerecor Reports Second Quarter 2019 Results -Positive Final Results with CERC-301 in nOH -First Patient Enrolled in CDG FIRST Trial - FDA Acceptance of IND Application of CERC-802 Rockville, MD
Cerecor Reports Second Quarter 2019 Results -Positive Final Results with CERC-301 in nOH -First Patient Enrolled in CDG FIRST Trial - FDA Acceptance of IND Application of CERC-802 Rockville, MD, August 08, 2019 - Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focuse
Read more →AVTXCerecor Appoints Keith Schmidt to its Board of Directors Rockville, MD
Cerecor Appoints Keith Schmidt to its Board of Directors Rockville, MD, June 12, 2019 - Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurolo
Read more →AVTXCerecor Reports First Quarter 2019 Results - Positive interim results from the Phase l study of CERC-301 in nOH -Positive results from Phase I Safety Data for CERC-801 in Healthy Volunteers Rockville, MD
Cerecor Reports First Quarter 2019 Results - Positive interim results from the Phase l study of CERC-301 in nOH -Positive results from Phase I Safety Data for CERC-801 in Healthy Volunteers Rockville, MD, May 9, 2019 - Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company f
Read more →AVTXCerecor Announces Leadership Changes Rockville, MD
Cerecor Announces Leadership Changes Rockville, MD - April 11, 2019 -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announc
Read more →AVTXJanuary 2019 Cerecor Corporate Highlights Cerecor Inc. Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-lo
January 2019 Cerecor Corporate Highlights Cerecor Inc. Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fac
Read more →AVTXCorporateHighlights 30th AnnualPiperJaffray Healthcare Conference LotteNew YorkPalace,New York November 27th, 2018 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the
CorporateHighlights 30th AnnualPiperJaffray Healthcare Conference LotteNew YorkPalace,New York November 27th, 2018 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-l
Read more →AVTXCerecor Reports Third Quarter 2018 Results BALTIMORE (Marketwired)
Cerecor Reports Third Quarter 2018 Results BALTIMORE (Marketwired) November 13, 2018 Cerecor Inc. ( Cerecor or the Company ) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and development capabilities, announced financial and
Read more →AVTXCorporate Overview Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies September 26 27, 2018 1 This presentation may include forward-looking statements made pursuant to the Private Securities Lit
Corporate Overview Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies September 26 27, 2018 1 This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are
Read more →AVTXCerecor to Acquire Ichorion Therapeutics Transaction worth approximately $26.5 Million in Stock plus potential milestones accelerates Cerecor s transformation strategy; Strengthens Rare Disease Pipeline and Expands Pedia
Cerecor to Acquire Ichorion Therapeutics Transaction worth approximately $26.5 Million in Stock plus potential milestones accelerates Cerecor s transformation strategy; Strengthens Rare Disease Pipeline and Expands Pediatric Portfolio BALTIMORE, MD September 25, 2018 Cerecor In
Read more →AVTXth Annual Global Investment Conference, sponsored by H.C. Wainwright September 4-6, 2018 1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litig
20th Annual Global Investment Conference, sponsored by H.C. Wainwright September 4-6, 2018 1 Forward-Looking Statements This presentation may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are
Read more →AVTXCerecor Reports Second Quarter 2018 Financial Results BALTIMORE (Marketwired)
Cerecor Reports Second Quarter 2018 Financial Results BALTIMORE (Marketwired) August 9, 2018 Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a difference in the lives of patients (
Read more →AVTXCerecor Appoints Simon Pedder to its Board of Directors BALTIMORE, MD
Cerecor Appoints Simon Pedder to its Board of Directors BALTIMORE, MD April 9, 2018 Cerecor, Inc. (NASDAQ: CERC), today announced that Simon C. Pedder, Ph.D. has been appointed to its Board of Directors. We are delighted to welcome Dr. Pedder to our Board. said Dr. Uli Hacksell
Read more →AVTXCerecor Appoints Peter Greenleaf as Chief Executive Officer BALTIMORE, MD
Cerecor Appoints Peter Greenleaf as Chief Executive Officer BALTIMORE, MD March 28, 2018 Cerecor, Inc. (NASDAQ: CERC) today announced that its Board of Directors has appointed Peter Greenleaf as Chief Executive Officer. Mr. Greenleaf has served on the Company s board since May 2
Read more →AVTXCerecor to Acquire Avadel Pharmaceuticals Pediatric Assets Transaction is immediately accretive to revenue and earnings Expands Cerecor s pipeline via an exclusive license to use Avadel s LiquiTime and Micropump technolo
Cerecor to Acquire Avadel Pharmaceuticals Pediatric Assets Transaction is immediately accretive to revenue and earnings Expands Cerecor s pipeline via an exclusive license to use Avadel s LiquiTime and Micropump technology in four pediatric drug candidates BALTIMORE, MD Februa
Read more →AVTXCerecor Acquires TRx Pharmaceuticals Addition of commercial franchise signals strategic shift toward pediatric healthcare Revenue stream to drive development of early-stage orphan drug candidates BALTIMORE
Cerecor Acquires TRx Pharmaceuticals Addition of commercial franchise signals strategic shift toward pediatric healthcare Revenue stream to drive development of early-stage orphan drug candidates BALTIMORE, Nov. 17, 2017 Cerecor Inc. (NASDAQ: CERC) and TRx Pharmaceuticals, LLC
Read more →AVTXCerecor Inc. Reports Second Quarter 2017 Financial Results Cash position improved by sale of CERC-501 BALTIMORE (Marketwired)
Cerecor Inc. Reports Second Quarter 2017 Financial Results Cash position improved by sale of CERC-501 BALTIMORE (Marketwired) August 14, 2017 Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsy
Read more →AVTXCERECOR INC. CLOSES $5.0 MILLION PRIVATE PLACEMENT Use of proceeds to advance development of CERC-611 and CERC-501 Annual stockholders meeting to be rescheduled to June 30 th , 2017 Baltimore, MD - (Marketwired) - 4/28/2
CERECOR INC. CLOSES $5.0 MILLION PRIVATE PLACEMENT Use of proceeds to advance development of CERC-611 and CERC-501 Annual stockholders meeting to be rescheduled to June 30th, 2017 Baltimore, MD - (Marketwired) - 4/28/2017 - Cerecor Inc. (NASDAQ: CERC), a clinical-stage biophar
Read more →AVTXSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2017 (Exact name of Registrant as Specified in Its Charter) Delaware 001-37590 45-0
Read more →AVTXRISK FACTORS Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and uncertainties described below together with all othe
Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks and uncertainties described below together with all other information contained in or incorporated by reference in our other fili
Read more →AVTXCerecor Announces At-the-Market Equity Offering Program BALTIMORE -- (Marketwired)
Cerecor Announces At-the-Market Equity Offering Program BALTIMORE -- (Marketwired) - January 27, 2017 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric
Read more →AVTXCerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal BALTIMORE--(Marketwired)--December 5, 2016--Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neu
Read more →AVTXCerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder
Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder CERC-301 misses primary endpoint but the 20 mg dose shows clinically meaningful efficacy signals at day 2 Management to Hold Conference Call and Webcast Today at 5:00 pm ET BALTIMORE--(Mark
Read more →AVTXCerecor Inc. Reports Third Quarter 2016 Financial Results BALTIMORE—(Marketwired)—
Cerecor Inc. Reports Third Quarter 2016 Financial Results BALTIMORE (Marketwired) November 8, 2016 Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and ps
Read more →Competitive Position
How AVTX ranks across every disease it competes inCompetitive Position is a premium feature
See how AVTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial